Opus Genetics (IRD) Debt Ratio (2021 - 2026)

Opus Genetics (IRD) posted quarterly Debt Ratio of 0.02 for Q1 2026, down 20.17% quarter-over-quarter from 0.02 in Q4 2025.

Opus Genetics (IRD) Debt Ratio (2021 - 2026) Analysis & Trends

Opus Genetics (IRD) has reported Debt Ratio for 4 consecutive years, with 0.02 the latest figure, recorded in Q1 2026.

In Q1 2026, Debt Ratio changed N/A year-over-year to 0.02; the TTM figure through Mar 2026 stood at 0.02 (changed N/A YoY), while the FY2025 annual figure was 0.02, changed N/A from the prior year.
Debt Ratio slipped to 0.02 in Q1 2026 per IRD's latest filing, from 0.02 in the prior quarter.
Across five years, Debt Ratio topped out at 0.03 in Q3 2025 and bottomed at 0.01 in Q1 2022.
Historically, Debt Ratio has averaged 0.02 across 3 years, with a median of 0.02 in 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	0.05
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	0.12
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	0.47
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	-
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	0.26
10	Opus Genetics	298.36 Mn	209.55 Mn	-	0.38

Download Data